Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease.
The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.
Bendheim
Paul E
PE
Minden BioPharmaceuticals, Ltd, Jerusalem, Israel. pbendheim@mindset.co.il
Poeggeler
Burkhard
B
Neria
Eyal
E
Ziv
Vivi
V
Pappolla
Miguel A
MA
Chain
Daniel G
DG
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D016874:Neurofibrillary Tangles / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects
D016229:Amyloid beta-Peptides; D000975:Antioxidants; D007211:Indoles; D018696:Neuroprotective Agents; C015292:indolepropionic acid